A U.S. district court judge found key claims of a Scale Biosciences patent invalid for lack of written description and enablement, handing Parse Biosciences a courtroom victory in a patent infringement battle over split‑pool single‑cell sequencing technologies. The memorandum opinion by Judge Christopher Burke struck down claims in U.S. Patent No. 11,634,752, which Scale (now owned by 10x Genomics) had asserted against Parse. Parse leveraged invalidity defenses to blunt enforcement of Scale’s patent portfolio; earlier in the year Parse succeeded in invalidating other 10x patents at the Patent Trial and Appeal Board. The ruling reduces legal overhang for Parse and underscores how patent disputes continue to shape competition among instrument‑free single‑cell providers. Both companies offer workflows designed to democratize single‑cell assays without specialized hardware, and this decision will factor into competitive positioning, licensing talks, and product roadmaps across the single‑cell market. Industry observers note that invalidation outcomes can tilt the balance toward faster adoption of lower‑cost single‑cell workflows and spur further litigation or licensing negotiations among major players.